The Guillain-Barré syndrome epidemiologic and clinical features

Hogg, Judith E.; Kobrin, Donald E.; Schoenberg, Bruce S.

doi:10.1016/0021-9681(79)90068-7

Cited by 28 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The unclear biomodality in age-specific incidences, perhaps due to truncated ages, is in line with other poorly defined age-specific profiles reported in small studies [23, 25, 28]and an increase with age in a register study in Ontario [32]. Nevertheless, it contrasts with bimodal shapes observed in other studies, with a valley at 35–39 years and a peak at 70–74 years of age [20, 30, 39].…”

Section: Discussionsupporting

confidence: 58%

See 1 more Smart Citation

Guillain-Barré Syndrome in Spain, 1985–1997: Epidemiological and Public Health Views

Cuadrado

Pedro‐Cuesta²,

Ara³

et al. 2001

Eur Neurol

View full text Add to dashboard Cite

Retrospective demographic information and hospital record data were collected for 337 patients resident in Spain who had validated Guillain-Barré syndrome (GBS) diagnoses and clinical onset during the period 1985–1997 and had been admitted to 11 centres, covering a population of 3.9 million. The European age-adjusted GBS incidence per 100,000 for 1985–1997 among the population aged 20 and over was 0.85, with a breakdown of 1.14 in men and 0.58 in women. Incidence increased with age and time, with occasional rises that mimicked outbreaks and occurred at irregular 2- to 4-year intervals, mainly in winter. Spatial variation was modest. Respiratory and gastrointestinal infections respectively constituted 49.3 and 19.3% of recorded preceding events. The 97.5% intercentile limit, obtained from the 1985–1997 monthly incidences using predictions from a Poisson model, was proposed as the threshold value for pilot epidemiological surveillance of GBS in 1998–1999.

show abstract

Section: Discussionsupporting

confidence: 58%

“…Compared to male/female (m/f) ratios reported world- wide [21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40], the sex differential in Spain (m/f rate ratio 2.02, crude m/f ratio 218/119 = 1.83) is the second highest, after that reported in a recent Italian study [22]. The reason for this difference is unknown.…”

Section: Discussionmentioning

confidence: 99%

Guillain-Barré Syndrome in Spain, 1985–1997: Epidemiological and Public Health Views

Cuadrado

Pedro‐Cuesta²,

Ara³

et al. 2001

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…[5][6][7][8][9][10][11][12][13][14] The children with Guillain-Barré syndrome not given intravenous immunoglobulin were analyzed.…”

Section: Methodsmentioning

confidence: 99%

Ten-Year Prospective Study (Clinical Spectrum) of Childhood Guillain-Barré Syndrome in the Arabian Peninsula: Comparison of Outcome in Patients in the Pre— and Post—Intravenous Immunoglobulin Eras

et al. 2003

View full text Add to dashboard Cite

A prospective study of Guillain-Barré syndrome from January 1992 to December 2001 was undertaken. Intravenous immunoglobulins were used in all patients. All patients were followed up until complete recovery. Various parameters, such as onset of weakness, duration of hospital stay, ventilation requirement, residual deficit, and mortality, were recorded. Acute relapses and fluctuations were also noted. The pattern of this group was compared with patients before 1992, who were not given intravenous immunoglobulins in the Sultanate of Oman. Our data were compared with a few studies prior to 1992 from the medical literature. Our study revealed a definite benefit with intravenous immunoglobulins. The disease course and hospital stay were shortened. Fewer patients needed ventilation. There was no mortality, and the residual deficit was less than 5%. Occasional relapses at a later stage in the course of illness have been noted in acute Guillain-Barré syndrome. However, acute relapse, a new phenomenon that was not seen in the pre-intravenous immunoglobulin era, stood at 11.9%. Intravenous immunoglobulins have made a significant difference in the outcome of Guillain-Barré syndrome, but one has to be aware of acute relapses, which usually occur in the first 2 to 3 weeks after administration.

show abstract

“…Laboratory studies showed the following results or values: serum urea, electrolytes, thyroxine, HBD, TPHA, and ANF, normal or negative; plasma glucose, normal; com¬ plete blood cell count, normal; chest roentgenogram, normal; and vitamin B12, 2000 pg/mL (1475 pmol/L). Laboratory studies of CSF showed the following results: IgG, 10.8 mg/dL (0.2 g/L); oligoclonal banding on electrophoresis; albuminocytological dissociation (total protein, 70.7 mg/dL [0.7 g/L] and lymphocyte count, 1/mm3 [1 X 10VL]). A blood test on admission showed a mild subclinical hepatitis with an AST level of 54 U/L.…”

mentioning

confidence: 99%

Sporadic Non-A, Non-B Hepatitis and Epstein-Barr Hepatitis Associated With the Guillain-Barre Syndrome

Macleod¹

1987

Archives of Neurology

View full text Add to dashboard Cite

The Guillain-Barré syndrome epidemiologic and clinical features

Cited by 28 publications

References 9 publications

Guillain-Barré Syndrome in Spain, 1985–1997: Epidemiological and Public Health Views

Guillain-Barré Syndrome in Spain, 1985–1997: Epidemiological and Public Health Views

Ten-Year Prospective Study (Clinical Spectrum) of Childhood Guillain-Barré Syndrome in the Arabian Peninsula: Comparison of Outcome in Patients in the Pre— and Post—Intravenous Immunoglobulin Eras

Sporadic Non-A, Non-B Hepatitis and Epstein-Barr Hepatitis Associated With the Guillain-Barre Syndrome

Contact Info

Product

Resources

About